In this video, Dr. Brian Schwartz highlights several small-molecule TKIs in development with the potential to help patients with several malignancies.
In this video, Dr. Brian Schwartz highlights several small-molecule TKIs in development with the potential to help patients with several malignancies.
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.